非苏拉赞和埃索美拉唑控制夜间胃食管反流症状的比较:一项随机交叉研究

IF 3.3 3区 医学 Q2 CLINICAL NEUROLOGY
Dong Jun Oh, Dong Hwan Park, Jiyun Jung, Yun Jeong Lim
{"title":"非苏拉赞和埃索美拉唑控制夜间胃食管反流症状的比较:一项随机交叉研究","authors":"Dong Jun Oh, Dong Hwan Park, Jiyun Jung, Yun Jeong Lim","doi":"10.5056/jnm25119","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Nocturnal acid reflux disrupts sleep and impairs quality of life. Proton pump inhibitors (PPIs) provide insufficient suppression of nocturnal acid secretion, whereas fexuprazan offers prolonged acid suppression. We compared the efficacy of fexuprazan and esomeprazole in controlling nocturnal reflux.</p><p><strong>Methods: </strong>In a randomized and crossover study, patients received fexuprazan or esomeprazole daily for 4 weeks, followed by a washout and crossover to the alternate medication for another 4 weeks, with a final washout completing the sequence. Severity (scores 0-10), frequency, sleep disturbance, and medication preferences were evaluated.</p><p><strong>Results: </strong>Thirty-nine patients were enrolled and randomized to receive either fexuprazan (n = 20) or esomeprazole (n = 19) first. After the first treatment, fexuprazan reduced severity from 7.5 ± 1.2 to 1.4 ± 1.0 (81% decrease), versus 7.5 ± 1.1 to 2.8 ± 1.5 (64% decrease) with esomeprazole (p = 0.012). In patients with severe symptoms (scores ≥ 7), fexuprazan led to significantly greater improvement than esomeprazole (p = 0.008). Following the first washout, the second crossover treatment resulted in greater improvement in symptom severity with fexuprazan (p = 0.001). During the second washout, nocturnal symptoms severity and frequencies were better controlled with fexuprazan than with esomeprazole (p = 0.005 and 0.019). Patients who switched from esomeprazole to fexuprazan preferred fexuprazan (p = 0.018).</p><p><strong>Conclusions: </strong>Fexuprazan was more effective than esomeprazole in controlling nocturnal reflux symptom, particularly in patients with severe symptoms. Fexuprazan may offer a therapeutic advantage for patients with severe and persistent nocturnal reflux despite PPI therapy.</p>","PeriodicalId":16543,"journal":{"name":"Journal of Neurogastroenterology and Motility","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study.\",\"authors\":\"Dong Jun Oh, Dong Hwan Park, Jiyun Jung, Yun Jeong Lim\",\"doi\":\"10.5056/jnm25119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aims: </strong>Nocturnal acid reflux disrupts sleep and impairs quality of life. Proton pump inhibitors (PPIs) provide insufficient suppression of nocturnal acid secretion, whereas fexuprazan offers prolonged acid suppression. We compared the efficacy of fexuprazan and esomeprazole in controlling nocturnal reflux.</p><p><strong>Methods: </strong>In a randomized and crossover study, patients received fexuprazan or esomeprazole daily for 4 weeks, followed by a washout and crossover to the alternate medication for another 4 weeks, with a final washout completing the sequence. Severity (scores 0-10), frequency, sleep disturbance, and medication preferences were evaluated.</p><p><strong>Results: </strong>Thirty-nine patients were enrolled and randomized to receive either fexuprazan (n = 20) or esomeprazole (n = 19) first. After the first treatment, fexuprazan reduced severity from 7.5 ± 1.2 to 1.4 ± 1.0 (81% decrease), versus 7.5 ± 1.1 to 2.8 ± 1.5 (64% decrease) with esomeprazole (p = 0.012). In patients with severe symptoms (scores ≥ 7), fexuprazan led to significantly greater improvement than esomeprazole (p = 0.008). Following the first washout, the second crossover treatment resulted in greater improvement in symptom severity with fexuprazan (p = 0.001). During the second washout, nocturnal symptoms severity and frequencies were better controlled with fexuprazan than with esomeprazole (p = 0.005 and 0.019). Patients who switched from esomeprazole to fexuprazan preferred fexuprazan (p = 0.018).</p><p><strong>Conclusions: </strong>Fexuprazan was more effective than esomeprazole in controlling nocturnal reflux symptom, particularly in patients with severe symptoms. Fexuprazan may offer a therapeutic advantage for patients with severe and persistent nocturnal reflux despite PPI therapy.</p>\",\"PeriodicalId\":16543,\"journal\":{\"name\":\"Journal of Neurogastroenterology and Motility\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurogastroenterology and Motility\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5056/jnm25119\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurogastroenterology and Motility","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5056/jnm25119","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:夜间胃酸反流扰乱睡眠,损害生活质量。质子泵抑制剂(PPIs)不能充分抑制夜间胃酸分泌,而非昔普拉赞能延长胃酸抑制。我们比较了非昔普拉赞和埃索美拉唑控制夜间反流的疗效。方法:在一项随机交叉研究中,患者每天服用非苏拉赞或埃索美拉唑,连续4周,然后进行洗脱和交叉治疗,再进行4周,最终洗脱完成该序列。评估严重程度(评分0-10分)、频率、睡眠障碍和药物偏好。结果:39例患者入组,随机分为两组,第一组接受非卓唑(n = 20)或埃索美拉唑(n = 19)。第一次治疗后,非卓唑将严重程度从7.5±1.2降低到1.4±1.0(降低81%),而埃索美拉唑将严重程度从7.5±1.1降低到2.8±1.5(降低64%)(p = 0.012)。在症状严重(评分≥7分)的患者中,非舒帕赞的改善效果明显大于埃索美拉唑(p = 0.008)。在第一次洗脱后,第二次交叉治疗导致非舒拉赞在症状严重程度上的更大改善(p = 0.001)。在第二次洗脱期,非舒拉赞组比埃索美拉唑组更能控制夜间症状的严重程度和频率(p = 0.005和0.019)。从埃索美拉唑切换到非苏普拉赞的患者更喜欢非苏普拉赞(p = 0.018)。结论:非舒拉赞在控制夜间反流症状方面比埃索美拉唑更有效,尤其是在症状严重的患者中。尽管有PPI治疗,但对于严重且持续的夜间反流患者,非舒拉赞可能具有治疗优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study.

Background/aims: Nocturnal acid reflux disrupts sleep and impairs quality of life. Proton pump inhibitors (PPIs) provide insufficient suppression of nocturnal acid secretion, whereas fexuprazan offers prolonged acid suppression. We compared the efficacy of fexuprazan and esomeprazole in controlling nocturnal reflux.

Methods: In a randomized and crossover study, patients received fexuprazan or esomeprazole daily for 4 weeks, followed by a washout and crossover to the alternate medication for another 4 weeks, with a final washout completing the sequence. Severity (scores 0-10), frequency, sleep disturbance, and medication preferences were evaluated.

Results: Thirty-nine patients were enrolled and randomized to receive either fexuprazan (n = 20) or esomeprazole (n = 19) first. After the first treatment, fexuprazan reduced severity from 7.5 ± 1.2 to 1.4 ± 1.0 (81% decrease), versus 7.5 ± 1.1 to 2.8 ± 1.5 (64% decrease) with esomeprazole (p = 0.012). In patients with severe symptoms (scores ≥ 7), fexuprazan led to significantly greater improvement than esomeprazole (p = 0.008). Following the first washout, the second crossover treatment resulted in greater improvement in symptom severity with fexuprazan (p = 0.001). During the second washout, nocturnal symptoms severity and frequencies were better controlled with fexuprazan than with esomeprazole (p = 0.005 and 0.019). Patients who switched from esomeprazole to fexuprazan preferred fexuprazan (p = 0.018).

Conclusions: Fexuprazan was more effective than esomeprazole in controlling nocturnal reflux symptom, particularly in patients with severe symptoms. Fexuprazan may offer a therapeutic advantage for patients with severe and persistent nocturnal reflux despite PPI therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Neurogastroenterology and Motility
Journal of Neurogastroenterology and Motility GASTROENTEROLOGY & HEPATOLOGY-CLINICAL NEUROLOGY
CiteScore
6.30
自引率
8.80%
发文量
96
期刊介绍: Journal of Neurogastroenterology and Motility (J Neurogastroenterol Motil) is a joint official journal of the Korean Society of Neurogastroenterology and Motility, the Thai Neurogastroenterology and Motility Society, the Japanese Society of Neurogastroenterology and Motility, the Indian Motility and Functional Disease Association, the Chinese Society of Gastrointestinal Motility, the South East Asia Gastro-Neuro Motility Association, the Taiwan Neurogastroenterology and Motility Society and the Asian Neurogastroenterology and Motility Association, launched in January 2010 after the title change from the Korean Journal of Neurogastroenterology and Motility, published from 1994 to 2009.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信